Our History
2024
March 2024：The Metagenomic PIM Max product was launched. February 2024：The Gene Sequencer GensKey S obtained Class III Medical Device Registration Certification. January 2024：The High-throughput Fully Automated Sample Preparation System received Class II Medical Device Registration Certification.
2023
November 2023： GensKey Medical passed the ISO27001 Information Security Management System Certification. November 2023：GensKey Medical successfully cleared the cfDNA mNGS Interlaboratory Quality Assessment conducted by the National Clinical Testing Center. June 2023：The PISA-MTB Targeted Detection Product for Tuberculosis was launched. May 2023：GensKey Medical attained ISO15189 Medical Laboratory Accreditation. May 2023, GensKey Medical was once again listed on the "Future Healthcare Top 100" list for 2023. March 2023：The PIM-G Gynecological Infection Detection Product was launched.
2022
December 2022：The PISA-R Targeted Detection Product for Respiratory Infection Pathogens was launched. November 2022：GenseqAMR 3.0 was officially launched. June 2022：TensKey Medical's Monkeypox Virus Nucleic Acid Detection Kit received EU CE Certification.
2021
December 2021: GensKey Medical received ISO9001:2015 Quality Management System Certification. July 2021: The mNGS Blood Panorama Version for pathogen detection in whole blood samples was launched. June 2021: GenseqAMR, a product for predicting molecular drug susceptibility phenotypes of antibiotic-resistant pathogens, was released. April 2021: Received strategic investment of hundreds of millions of RMB from CPE, Oriza Seed, and Taikang Insurance.
2020
November 2020: Secured over RMB two hundred million in Series C financing from Huagai Capital, Apricot Capital, and Yuanbio Venture Capital. July 2020: GensKey Medical’s "Sequencing Data Analysis Software for Pathogenic Microorganisms" successfully obtained Class II Medical Device Registration Certification. April 2020: The full suite of GensKey Medical's COVID-19 testing products (Colloidal Gold, PCR, and mNGS) received EU CE certification.
2019
November 2019: Secured RMB hundreds of millions in Series B financing from SoftBank China Venture Capital, Fortune Capital, LGIMIC Venture Capital，Yuanju Capital. May 2019: Launched PIM Metagenomic Pathogen Detection Product. March 2019: Received tens of millions in strategic investment from Legend Capital, becoming the first company in China's field of pathogen metagenomic testing to secure funding.
2018
November 2018: Beijing GensKey Medical entered the Changping Zhongguancun Life Science Park. March 2018: GensKey Medical Technology was registered and established in Wuqing, Tianjin.